

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-17. Cancelled.

18. (Currently Amended) An isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base wherein [[::]] said molecule comprises a sequence of bases identified in SEQ. ID. NO. 41.

~~at least ten contiguous bases have a sequence complementary to a contiguous sequence of bases in SEQ ID NO 1, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof;~~

~~no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and~~

~~the molecule is capable of inhibiting microRNP activity.~~

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Original) A molecule according to claim 18, wherein at least one of the moieties is a modified deoxyribonucleotide moiety.

24. (Original) A molecule according to claim 23 wherein the modified deoxyribonucleotide is a phosphorothioate deoxyribonucleotide moiety.

25. (Original) A molecule according to claim 23, wherein the modified deoxyribonucleotide is N'3-N'5 phosphoroamidate deoxyribonucleotide moiety.

26. (Original) A molecule according to claim 18, wherein at least one of the moieties is a modified ribonucleotide moiety.

27. (Original) A molecule according to claim 26, wherein the modified ribonucleotide is substituted at the 2' position.

28. (Original) A molecule according to claim 27, wherein the substituent at the 2' position is a C₁ to C₄ alkyl group.

29. (Original) A molecule according to claim 28, wherein the alkyl group is methyl.

30. (Original) A molecule according to claim 28, wherein the alkyl group is allyl.

31. (Original) A molecule according to claim 27, wherein the substituent at the 2' position is a C₁ to C₄ alkoxy - C₁ to C₄ alkyl group.

32. (Original) A molecule according to claim 31, wherein the C₁ to C₄ alkoxy - C₁ to C₄ alkyl group is methoxyethyl.

33. (Original) A molecule according to claim 26, wherein the modified ribonucleotide has a methylene bridge between the 2'-oxygen atom and the 4'-carbon atom.

34. (Original) A molecule according to claim 18, wherein at least one of the moieties is a peptide nucleic acid moiety.

35. (Original) A molecule according to claim 18, wherein at least one of the moieties is a 2'-fluororibonucleotide moiety.

36. (Original) A molecule according to claim 18, wherein at least one of the moieties is a morpholino phosphoroamidate nucleotide moiety.

37. (Original) A molecule according to claim 18, wherein at least one of the moieties is a tricyclo nucleotide moiety.

38. (Original) A molecule according to claim 18, wherein at least one of the moieties is a cyclohexene nucleotide moiety.

39. (Original) A molecule according to claim 18, wherein the molecule is a chimeric molecule.

40. (Original) A molecule according to claim 18, wherein the molecule comprises at least one modified moiety for increased nuclease resistance.

41. (Original) A molecule according to claim 40, wherein the nuclease is an exonuclease.

42. (Original) A molecule according to claim 41, wherein the molecule comprises at least one modified moiety at the 5' end.

43. (Original) A molecule according to claim 41, wherein the molecule comprises at least two modified moieties at the 5' end.

44. (Original) A molecule according to claim 41, wherein the molecule comprises at least one modified moiety at the 3' end.

45. (Original) A molecule according to claim 41, wherein the molecule comprises at least two modified moieties at the 3' end.

46. (Original) A molecule according to claim 41, wherein the molecule comprises at least one modified moiety at the 5' end and at least one modified moiety at the 3' end.

47. (Original) A molecule according to claim 41, wherein the molecule comprises at least two modified moieties at the 5' end and at least two modified moieties at the 3' end.

48. (Original) A molecule according to claim 41, wherein the molecule comprises a cap at the 5' end, the 3' end, or both ends of the molecule.

49. (Original) A molecule according to claim 48, wherein the molecule comprises a chemical cap.

50. (Original) A molecule according to claim 48, wherein the molecule comprises an inverted nucleotide cap.

51. (Original) A molecule according to claim 40, wherein the nuclease is an endonuclease.

52. (Original) A molecule according to claim 51, wherein the molecule comprises at least one modified moiety between the 5' and 3' end.

53. (Original) A molecule according to claim 51, wherein the molecule comprises a chemical cap between the 5' end and 3' end.

54. (Original) A molecule according to claim 18, wherein all of the moieties are nuclease resistant.

55-67. (Cancelled)